CG Oncology, Inc. (CGON) Stock Price & Analysis

CG Oncology, Inc. (CGON) closed at USD 63.47 on Thursday, October 29, 2026, down 0.77% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 63.96; the Oct 29, 2026 session ranged USD 63.08–65.59 on volume of 782,614 shares. Market capitalization is $5.63B, with a 52-week range of USD 35.8–80.97 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:42 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CGON.md

Key facts (CGON)

• Last four reported quarters (through Jun 30, 2026): revenue $6.2M, net income -$224M (-3602.7% margin), free cash flow -$179M (SEC filings).
• Insider open-market sales, last ~7 months: 10 Form 4 filings, $4.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $24.8M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.80 on a 1–5 scale) (15 analysts), mean target USD 91.08 (range 79–108).
• Total return with dividends: 1Y +49.5% vs S&P 500 +14.4%; 5Y +81.2% vs S&P 500 +79.1%.
• Next earnings: 2026-11-09 (date not yet confirmed by the company), EPS estimate USD -0.81, revenue estimate $534K. All companies reporting that day: https://nexqual.com/earnings/2026-11-09
• Dividend: CGON paid no cash dividend in the last five years.
• Short interest: 10.19% of float (as of 2026-10-15), 8.1 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CGON)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CGON)

P/S 903.3x · EV/Sales 738.7x · P/B 5.5x · FCF yield -3.19% · Earnings yield -3.99% · Net cash $1.03B · EV $4.60B

Insider sales (SEC Form 4, open-market, last ~7 months) (CGON)

10 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (CGON)

1 purchase, $24.8M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (CGON)

Consensus Buy (mean 1.80 on a 1–5 scale), 15 analysts; mean target USD 91.08 (low 79, high 108).

Rating changes, last 120 days:

Total return (dividends reinvested) (CGON)

Dividends (CGON)

CGON paid no cash dividend in the last five years.

Short interest (CGON)

8,873,120 shares sold short, 10.19% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 11,254,500 shares (-21.2%). Days to cover: 8.1 (short shares ÷ average daily volume).

CGON earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

CGON recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

CGON suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 27, 2026.

CGON company outlook (results filed Aug 6, 2026)

• “The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029. 2 | • Research and Development (R&D) Expenses : R&D expenses were $54.7 million for the second quarter of 2026, as compared to $31.3 million for the prior year period.”

Quoted word-for-word from the SEC 8-K results press release.

CGON analyst estimates and revisions

CGON options: expected move

Options price a move of about ±22.5% (±$14.30) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±5.3% on average.

30-day implied volatility 121.7% vs 44.7% realized over the last 30 trading days. Put/call ratio (volume) 0.6. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 23:42 UTC)

Technical Analysis (CGON)

Nexqual's technical model rates CGON "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 23:42 UTC.

Analyst Ratings (CGON)

Wall Street analysts rate CGON "Buy" based on 15 analysts, with a mean price target of USD 91.08 (range USD 79–108), per Nexqual as of October 29, 2026 at 23:42 UTC.

Earnings (CGON)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 23:42 UTC.

Financials & Fundamentals (CGON)

Source: Nexqual, October 29, 2026 at 23:42 UTC.

Financial Health Score (CGON)

Nexqual rates CG Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 23:42 UTC.

Ownership (CGON)

Source: Nexqual, October 29, 2026 at 23:42 UTC.

Leadership (CGON)

CG Oncology, Inc. is led by Arthur Kuan, President, Chairman & CEO, per Nexqual as of October 29, 2026 at 23:42 UTC.

Major Backers & Investors (CGON)

Notable institutional backers of CG Oncology, Inc. include RTW Investments LP, T. Rowe Price, Decheng Capital LLC, according to Nexqual as of October 29, 2026 at 23:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 23:42 UTC.

From CG Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe our strategic CMC approach will potentially enable us to maintain an attractive cost of goods while rapidly achieving commercial scalability, if cretostimogene receives FDA approval.
• We believe our approach is supported by the February 2018 draft FDA guidance, revised in August 2024, regarding clinical trial design targeting BCG-unresponsive, CIS-containing NMIBC that stated that a single-arm trial with CR rate as the primary endpoint, taking DOR into account, may be appropriate for full approval.
• We believe our approach to combine cretostimogene with other therapeutics across several bladder cancer indications may enhance the potential utility of our product candidate beyond our core strategy of targeting intermediate- and high-risk NMIBC via cretostimogene monotherapy.
• We believe this concentration will potentially enable us to efficiently reach a large portion of our addressable market with a relatively small commercial footprint.

Partnerships

• We entered into a clinical trial collaboration and supply agreement with Merck providing at no-cost supply of pembrolizumab for use in CORE-001 (which agreement also provides for the joint ownership of clinical trial data but has no additional financial obligations and terminates upon conclusion of the trial).

Legal & Regulatory Risks (Item 1A, quoted)

• We make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.
• Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials or preclinical studies could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects.
• We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• We have not as an organization completed submission of a BLA, and we may be unable to do so for cretostimogene or any future product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:42 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt